This company has been acquired
RXDX Stock Overview
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Prometheus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$199.92 |
| 52 Week High | US$199.98 |
| 52 Week Low | US$25.65 |
| Beta | -0.49 |
| 11 Month Change | 3.51% |
| 3 Month Change | 77.52% |
| 1 Year Change | 684.31% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 690.51% |
Recent News & Updates
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Shareholder Returns
| RXDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.6% | 2.3% |
| 1Y | 684.3% | 23.6% | 35.1% |
Return vs Industry: RXDX exceeded the US Biotechs industry which returned 20.6% over the past year.
Return vs Market: RXDX exceeded the US Market which returned 17.7% over the past year.
Price Volatility
| RXDX volatility | |
|---|---|
| RXDX Average Weekly Movement | 20.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RXDX's share price has been volatile over the past 3 months.
Volatility Over Time: RXDX's weekly volatility has decreased from 26% to 20% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 97 | Mark McKenna | www.prometheusbiosciences.com |
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases.
Prometheus Biosciences, Inc. Fundamentals Summary
| RXDX fundamental statistics | |
|---|---|
| Market cap | US$9.56b |
| Earnings (TTM) | -US$150.56m |
| Revenue (TTM) | US$4.00m |
2,393x
P/S Ratio-63.5x
P/E RatioIs RXDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXDX income statement (TTM) | |
|---|---|
| Revenue | US$4.00m |
| Cost of Revenue | US$121.34m |
| Gross Profit | -US$117.34m |
| Other Expenses | US$33.22m |
| Earnings | -US$150.56m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.15 |
| Gross Margin | -2,937.17% |
| Net Profit Margin | -3,768.76% |
| Debt/Equity Ratio | 0% |
How did RXDX perform over the long term?
See historical performance and comparison